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The short- and longer-term effectiveness of a brief, 
multidisciplinary itch-coping group training scheme in 
adults with atopic dermatitis was evaluated. Clinical se-
verity scores (Eczema Area and Severity Index) and va-
lidated self-report measures were obtained in a waiting-
list control condition (n = 30) and a treatment condition 
(n = 61) at pre- and post-treatment and in the treatment 
condition at 3- and 12-month follow-ups. Relative to the 
control condition, all post-treatment measures showed 
improvements in terms of enhanced skin status, reduced 
itching and scratching and improved itch-coping pat-
terns. In the treatment condition, the changes were sus-
tained or further improved at both follow-ups. Also, the 
dermatological healthcare use was significantly reduced 
during the follow-up periods, in terms of fewer visits to 
the dermatologist and decreased use of topical cortico-
steroids and itch-relieving medication (histamine antago-
nists). The brief multidisciplinary itch-coping program-
me in adults with atopic dermatitis considerably reduced 
itch-scratching patterns, improved their skin status and 
reduced the use of dermatological care, both in the short 
and longer term. Key words: itch; scratching; cognitive 
behaviour therapy; atopic dermatitis; quality of life.
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Chronic itch is the main symptom of atopic dermatitis 
(AD) (1–8). As an adjunct to standard dermatological 
care, multidisciplinary itch-coping programmes have 
been developed (9–12; see 13 for a review). These 
programmes usually make use of a broad scope of 
cognitive-behavioural methods for the reduction of 
itch and scratching behaviour, including self-monito-
ring, guidance in skin care and coping skills to manage 
itch- and scratch-triggering factors, stress-management 
methods with relaxation techniques and habit reversal 
(9–12, see 13 for a review). Our group has developed 
a concise multidisciplinary group training itch-coping 
scheme for adults with AD. We needed to demonstrate 
the programme’s efficacy in the short and longer term. 
The main goals of the present study were:
• to compare the effects of the brief multidisciplinary 
itch-coping programme in a cohort of adult AD patients 
with a waiting-list control condition on the primary 
outcome measures itch, and the secondary outcome 
measures skin severity, scratching behaviour, itch-
coping patterns, illness cognitions and health-related 
quality of life;
• to determine the changes at 3 and at 12 months after treat-
ment completion in the primary and secondary outcome 
measures as well as in the use of dermatological care.
METHODS
Patients and procedure 
The study includes a treatment evaluation (n = 61) during four 
assessment points: pre- and post-treatment and 3 and 12 month 
follow-up assessments. In addition, changes during treatment are 
compared with a waiting-list control condition (n = 30) during 
3 months.
For the treatment condition, data were available for 61 
patients. Inclusion criteria were: age 16 years or older, and 
a diagnosis of AD with itch-scratching problems. Exclusion 
criteria were: severe physical or psychiatric co-morbidity that 
was likely to interfere with the training, insufficient command 
of the Dutch language, unwillingness to participate in a group 
context and lack of itch or scratching symptoms during the 
previous 3 months. Patients had a mean age of 37.0 years (stan-
dard deviation (SD) 13.7, range 17–70 years) and 68% were 
women. Sixty percent were married and 60% had completed 
up to 12 years of formal education. The group’s mean duration 
of illness was 23.1 years (SD 17.8; range 0–67 years). As part 
of the intake procedure, patients were asked to participate in 
the study and to complete self-report inventories and clinical 
assessments on four separate occasions, i.e. before and after 
the training programme and at a 3- and a 12-month follow-up. 
Thirty patients had additionally entered a waiting list of (at 
least) 3 months. At the start and end of this period they com-
pleted two assessments, the outcomes of which were used to 
compare them with the pre-post-treatment assessments of the 
treatment group (n = 61). 
Multidisciplinary itch-coping programme 
Each group programme included between five and eight partici-
pants and was delivered by two therapists: a clinical psycholo-
gist/cognitive behaviour therapist together with a dermatology 
nurse specialist, in adjunct to the patients’ regular visits to their 
dermatologist. The therapists were specifically trained in group 
therapy as well as itch-scratching cognitive-behavioural meth-
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ods, based on a written patient manual (see Table I). The group 
programme comprised four 2-weekly sessions and one booster 
session one month after treatment end (all conducted within a 
3-month period), followed by one individual booster session 
3 months later. During treatment, all participants were given a 
booklet containing information about the programme’s content 
and exercises and the daily homework assignments (requiring 
approximately 1 h). To secure an optimal commitment, parti-
cipants were also encouraged to look for at least one involved 
significant person in their immediate environment to support 
them throughout the training programme. The protocol was 
based on existing cognitive-behavioural programmes that had 
been shown to be effective in enhancing itch-coping skills and 
reducing scratching behaviour. The methods included self-
 monitoring, improving skin-care management, coping techniques 
to deal with triggering factors of itching and scratching, stress-
management and habit reversal (9–13). In each session (duration 
2 h) both itch- and scratch-related issues were addressed. Table 
I provides a schematic overview of the programme. 
Outcome measures
The following validated clinical and self-reported measures 
were completed at all assessments:
A clinical evaluation of skin severity was performed by an 
independent, trained research assistant who was blind to the 
study protocol using the validated Eczema Area and Severity 
Index (EASI), which includes the total affected body area and 
signs of skin severity of erythema, induration/papulation, ex-
coriation, and lichenification for patients with AD (14).
Skin status was measured with the skin-status scale of the 
Impact of Chronic Skin Disease on Daily Life (ISDL), a multi-
dimensional self-inventory of health status for patients with 
chronic skin diseases that reflects physical, psychological and 
social- health aspects (1, 2). All ISDL scales relevant for itch-
 coping problems (9 out of 14 scales) were used in the present 
study. The skin status scale assesses the current extent and 
severity of the skin condition for nine different body parts (face, 
hairy scalp, neck, hands, arms, torso, legs, feet and genitals/anus). 
The sum score reflects the overall severity of the skin condition.
Itch was assessed with the 4-item itch scale of the ISDL (2) 
to establish the intensity and duration of the itch complaints 
during the past 4 weeks. For AD, a Cronbach’s alpha of 0.83 
has been reported (1, 2). 
Scratch responses were assessed with three ISDL scales (2): 
(i) conscious scratching to evaluate the frequency and duration 
of the scratching behaviour (3 items); (ii) automatic scratching 
to gauge scratching behaviour to non-itching stimuli and un-
conscious scratching behaviour (e.g. scratching in the absence 
of itch or without being aware of it; 3 items); and (iii) scratching 
at night to determine the frequency of scratching behaviour 
during sleep (1 item). For the conscious and automatic scrat-
ching scales Cronbach’s alphas of 0.73 and 0.64, respectively, 
have been reported in AD (2).
Itch-coping patterns were evaluated by means of two scales 
derived from self-report tools used in chronic pain research. The 
6-item itch-efficacy scale was adapted from the Arthritis-Self-Effi-
cacy questionnaire (ASE; 15) and the 13-item itch-catastrophizing 
scale from the Pain Catastrophizing Scale (PCS) (16) by replacing 
the word “pain” by “itch” in the relevant places. Cronbach’s alphas 
for both scales were 0.78 and 0.93, respectively.
Health-related quality of life was assessed with the Disease Im-
pact on Daily Life scale of the ISDL (also referred to as daily-life 
impact; 1, 2). This 10-item generic scale measures the effect the 
condition has on activities of daily life including work, hobbies, 
holiday, sleep, sexuality, eating and relationships. A Cronbach’s 
alpha of 0.87 has been reported for AD (2). We also assessed 
disease-related quality of life with a Dutch version of the 
DLQI (Dermatological Life Quality Index (DLQI);17), a 10-
item scale measuring the impact of skin diseases on several 
physical, psycho logical and social aspects of daily life, with a 
Cronbach’s alpha of 0.86. 
Illness Cognitions were appraised using three chronic-disease-
related cognitions of the ISDL (2, 18): helplessness (6 items), accep-
tance (6 items) and perceived benefits (6 items), with Cronbach’s 
alphas in AD of 0.88, 0.93 and 0.85, respectively (1, 2, 18).
Dermatological care use was assessed with a self-report ques-
tionnaire that gauges the patient’s healthcare consumption by 
asking about the number of outpatient visits to their dermatologist 
during the past 3 months and referrals for treatment at our day 
clinic or inpatient stays at the dermatology department. Patients 
also detailed the prescribed medication they had used during the 
past 3 months, including topical corticosteroids (classified in 
accordance with the British National Formulary (19) into mild, 
moderately potent, potent and very potent), and itch-relieving 
medication (histamine antagonist).
Statistical analyses
Differences between drop-outs and completers, responders and 
non-responders, as well as between the control and treatment 
condition at pre-treatment, were tested with χ2 analyses and 
Student’s t-tests with a threshold of p < 0.05 (two-tailed). 
For evaluation of the treatment, we conducted analyses of 
covariance (ANCOVA) to assess changes in the treatment 
and control conditions as to the primary outcomes of itch and 
secondary outcomes of skin severity, scratching behaviour, 
itch-coping patterns, health-related quality of life and illness 
cognitions, using the baseline measures of the treatment and 
waiting list control condition as covariates. Paired t-tests were 
subsequently conducted on the primary and secondary outcomes 
separately for both conditions. 
ANOVA with repeated measurements was conducted for all as-
sessment points of the treatment condition (pre- and post- treatment 
and 3 and 12 month follow-up). In addition, paired t-tests and 
Wilcoxon signed-rank test between the pre-treatment and both the 
3- and 12-month follow-up data were also performed on the pri-
mary and secondary outcomes and dermatological care to explore 
the changes from pre-treatment to follow-up assessments. 
To gain insight into the magnitude of effects, moderate (about 
0.50) and large (about 0.70) effect sizes were used as possible 
indicators of clinically relevant changes, which were calculated 
by the difference between the means of the various measure-
ments divided by their pooled SD (20). To establish the number 
of patients with clinically significant improvements, we compu-
ted the percentages of patients that had improved at least 25% 
in the EASI scores as well as the proportion of patients having 
reached significant skin clearance in the EASI score (in terms 
of < 10% of the skin being affected) for all assessments.
Table I. Overview of the content of the treatment manual and 
sessions of the multidisciplinary itch-coping training programme 
Theme 1 Theme 2
Session 1 Introduction Registration and self-
monitoring
Session 2 Skin care Habit reversal
Session 3 Itch-triggering factors Scratch-triggering factors 
Session 4 Stress-management Long-term goals and relapse 
prevention
Booster 
session 
Long-term goals and relapse 
prevention 
Acta Derm Venereol 89
59Itch-coping training programme
During the treatment evaluation, pre-to-post-treatment data of 
61 patients and for the 3 and 12 month follow-up data of 55 and 
40 patients were available, respectively. The missing follow-up 
data are due to ongoing data collection (4 and 9 patients for 
the 3 and 12 months follow-up, respectively). The two other 
non-responders at first follow-up had developed physical co-
morbidities during the 3-month period. Of the non-responding 
patients at the second follow-up, five had developed physical 
co-morbidity during the later 12 months follow-up period and 
three had moved; of the other four the reason for not responding 
could not be established. χ2 and t-tests of the pre-treatment data 
between responders and non-responders revealed no significant 
differences between the two groups with regard to any of the 
demographic variables (sex, age, educational level, marital 
status), disease duration or primary and secondary outcome 
measures. All treatment analyses were consequently conducted 
on the full pre-to-post data sets (n = 61) and the complete pre-
to-follow-up data sets of the treatment condition (n = 40). Since 
both methods revealed the same overall results, only the results 
of the complete pre-to-follow-up data sets of the treatment 
condition (n = 40) are presented.
RESULTS
Drop-outs and pre-treatment comparisons
Only two of 61 patients (3%) dropped out during the 
programme, both due to insufficient motivation to 
continue with the training because of their relatively 
low itch levels. Attendance of sessions was generally 
high for patients, since at least 4 of the 5 group sessions 
and the individual session were attended by more than 
90% of the patients. 
Table II lists the means and SDs of all primary and 
secondary outcome measures for the treatment and 
control conditions separately. Baseline comparisons 
revealed no significant differences between the two 
conditions on any of the demographic variables or 
measures, duration of disease or primary and secondary 
outcome measures.
Changes during treatment
ANCOVA for the two conditions (treatment vs. waiting 
list control condition) revealed significant F-changes on 
the primary outcome of itch and the secondary outcome 
of the clinical and subjective measures of skin severity, 
scratching behaviour, itch-coping patterns (self-effica-
cy, catastrophizing) and illness cognitions (acceptance, 
perceived benefits) for the treatment condition relative 
to the control condition (see Table II). No significant 
differences were found for both health-related quality 
of life measures (ISDL impact and DLQI). 
When examining the nature of the changes in both con-
ditions, the paired t-tests of the pre- and post-treatment 
data in the treatment condition further showed that the 
primary outcome of itch in the treatment condition had 
significantly decreased. This was also the case for all 
secondary outcomes: clinical and self-reported outcomes 
of skin severity and scratching behaviour (conscious and 
automatic scratching, scratching at night) had decreased, 
itch-coping patterns had improved through increased 
self-efficacy and decreased catastrophizing, health-rela-
ted quality-of-life scores (ISDL impact and DLQI) were 
higher and patients had acquired more beneficial illness 
cognitions in terms of a decrease in helplessness and a 
rise in acceptance and perceived benefits (see Table II). In 
contrast, none of these measures showed any significant 
changes for the patients during the waiting-list period. 
Changes at 3- and 12-month follow-ups
Long-term changes for the treatment condition were 
explored by ANOVA with repeated measurements for 
the treatment condition during all four assessment 
points (pre- and post-treatment and 3- and 12-month 
follow-up assessments). Results indicated significant 
changes for the treatment group in all primary and 
secondary outcome measures (see Table III): patients 
in the treatment condition significantly improved with 
regard to itch, clinical and self-report measures of skin 
severity, scratching responses, itch-coping patterns, 
illness cognitions and health-related quality of life 
(DLQI and ISDL impact). In addition, the paired t-tests 
between the pre-treatment and the two follow-up data 
sets yielded almost the same significant changes as the 
pre-to-post-treatment analyses had yielded, indicating 
sustained improvements or even further augmentation 
of earlier improvements during the 3 and 12 months fol-
lowing treatment completion (see Table III). This means 
patients in the treatment condition significantly impro-
ved on all primary and secondary outcome measures 
of clinical and self-report measures of skin severity, 
itch, scratching responses, itch-coping patterns, illness 
cognitions and health-related quality of life at both the 
3- and 12-month follow-up assessments. 
Additional analyses of the changes in the extent of 
dermatological care showed that the number of der-
matological outpatient consultations was significantly 
reduced during both follow-up periods relative to the 
pre-treatment outcomes (p < 0.001 for both periods; 
see Table IV). The same was true for the incidence of 
dermatological day care: referrals to the day clinic had 
significantly decreased during both follow-up periods 
(p < 0.001 for both periods, respectively), which implied 
that none of the patients had received such care. Only 
one patient was referred to an inpatient stay during the 
3-month follow-up and none received such care during 
the 12-month follow-up. The use of itch-relieving medi-
cation or topical corticosteroids had also not changed 
significantly after three months. However, the 12-month 
follow-up did reveal significant drops in the use of itch-
relieving medication (histamine antagonist) (p < 0.01) 
and decreased use of topical corticosteroids (p < 0.05). 
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Effect sizes and clinically significant improvements
With regard to the magnitude of the observed changes 
in the outcome measure itch and skin severity in the 
treatment condition (see Table V), effect sizes indicated 
medium to large post-treatment and 3 and 12 month 
follow-up effects for skin severity (between 0.46 and 
0.85) and itch (between 0.88 and 1.37), whereas in the 
control condition the data reflected only small impro-
vements or a worsening of symptoms (skin severity 
–0.11; itch 0.24) (20). In terms of number of patients 
with clinical significant changes of the affected skin, 
the EASI area scores had improved at least 25% in the 
treatment condition in 39–56% of the patients at post-
treatment and the 3 and 12 month follow-ups, respec-
tively, in contrast to an improvement of not more than 
21% in the control condition. As to post-treatment and 
at 3 and 12 months follow-ups, there was skin clearance 
(affected area score < 10%) in 47–52% of the patients 
in the treatment condition at the different assessment 
points vs. 28% in the control condition. 
Patient satisfaction 
At the end of the fifth group (booster) session, patients 
were asked to complete an evaluation form. The scores 
on a 4-point Likert scale indicated that the patients were 
highly satisfied with the overall training programme 
(M = 3.71; SD = 0.46, range 1–4). They also rated the 
relevance of the various programme components separa-
tely (1 = not important, 4 = very important) and indicated 
the following elements as most important: skin care 
(M = 3.48; SD = 0.73, range 1–4), identification of and 
coping with itching and scratching triggering factors 
(M = 3.28; SD = 0.77, range 1–4), habit reversal (M = 3.10; 
SD = 0.79, range 1–4), and self-monitoring of itch and 
scratching behaviour (M = 3.02; SD = 0.81, range 1–4). 
They also gave relatively high importance ratings on the 
6-point Likert scales for multidisciplinary team (M = 5.52; 
SD = 0.80, range 1–6), the group character of the training 
(M = 5.23; SD = 1.07, range 1–6), the patient booklet 
(M = 4.98; SD = 0.98, range 1–6) and the homework as-
signments (M = 4.16; SD = 1.28, range 1–6). 
Table II. Mean and standard deviation (SD) for the treatment condition (TC) and waiting-list control condition (CC) for the primary and 
secondary outcome measures during pre- and post-treatment
Pre-treatment 
Mean (SD)
Post-treatment 
Mean (SD) F-value1 T-value2
Skin severity
EASI score
Skin status
TC
CC
TC
CC
  7.73 (6.80)
  8.39 (7.80)
17.73 (3.69)
16.38 (2.90)
  6.27 (5.84)
  9.28 (10.39)
15.92 (2.92)
16.73 (3.41)
5.50a
4.44a
  2.53a
–0.83
  3.37b
–0.59
Itch TC
CC
10.64 (2.98)
10.36 (3.46)
8.20 (2.54)
9.58 (3.10)
6.23a   5.09c
  1.50 
Scratch responses
Conscious scratching TC
CC
8.53 (2.80)
7.62 (2.99)
6.63 (2.95)
7.94 (2.97)
5.36a   3.81c
–0.47
Automatic scratching TC
CC
5.97 (2.32)
5.44 (2.04)
4.66 (1.77)
5.73 (2.29)
7.31b   3.50c
–0.66
Scratching at night TC
CC
2.32 (1.07)
2.29 (1.16)
1.79 (0.96)
2.25 (1.11)
4.48a   3.77c
  0.17
Itch-coping-patterns
Itch self-efficacy TC
CC
14.41 (4.54)
15.31 (4.54)
19.26 (4.57)
15.4 (5.05)
15.41c –6.08c
–0.17
Itch catastrophizing TC
CC
23.60 (9.71)
19.58 (8.50)
17.18 (9.44)
18.83 (11.34)
5.24a   5.42c
  0.42
Health-related quality of life 
Impact disease daily life TC
CC
22.39 (6.20)
21.69 (5.08)
20.25 (6.03)
20.32 (6.29)
0.42   3.71c
  1.17
Dermatology Life Quality 
(DLQI)
TC
CC
10.61 (6.82)
  9.50 (6.32)
  8.51 (5.00)
  9.32 (7.06)
0.73   2.39a
  0.10
Illness cognitions
Helplessness TC
CC
12.18 (4.15)
12.00 (3.12)
11.11 (3.00)a
10.96 (4.08)
0.04   2.07a
  1.79
Acceptance TC
CC
13.74 (3.74)
15.00 (4.07)
15.47 (3.48)b
13.92 (4.27)
8.52b –3.45c
  1.44
Perceived benefits TC
CC
11.08 (3.46)
12.00 (3.70)
12.43 (4.11)b
11.52 (3.63)
6.18a –3.24b
  0.88
ap < 0.05; bp < 0.01; cp < 0.001.
1F-value: analyses of covariance effects between TC and CC.
2T-value: paired t-tests for differences between pre- and post-treatment scores for the TC and waiting list CC.
EASI: Eczema Area and Severity Index.
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DISCUSSION
Itch and related scratching problems constitute a major 
problem in patients with AD (1–8). On the basis of 
multidisciplinary itch treatment schemes (9–13), in 
the present study we examined the short- and longer-
term effectiveness of a brief, multidisciplinary group 
treatment aimed at enhancing the itch-coping skills for 
patients with AD. 
The results showed the training programme to be effec-
tive in comparison with a waiting list control condition. 
Moreover, both the clinical and self-reported skin-status 
measures showed a significant reduction in the area of 
affected skin and skin severity at all measurements, with 
at least 25% improvement and/or clearance in more than 
half of the patients at 12 months follow-up. Also the other 
secondary outcome measures reflected clear improve-
ments: all modes of scratching responses (conscious, 
automatic and night-time scratch ing) had decreased, 
itch-coping patterns had improved in that itch-related 
self-efficacy was enhanced and itch catastrophizing 
reduced; changes in illness cognitions had been achie-
ved as reflected by the higher levels of acceptance and 
perceived benefits; and health-related quality of life was 
rated higher on all areas of daily living (work and leisure 
time, social activities or relationships). 
With our study we have extended earlier findings 
by showing that even a very brief, multidisciplinary 
treatment scheme for patients suffering from AD com-
Table III. Mean and standard deviation (SD) for the treatment condition (TC) at all four assessments points for the primary and secondary 
outcome measures 
Pre-treatment 
Mean (SD)
Post-treatment 
Mean (SD)
3-month
follow-up 
Mean (SD)
12-month 
follow-up 
Mean (SD) F-value1 
T-value2
3-month 
follow-up 
T-value2
12-month 
follow-up
Skin severity
EASI score
Skin status
  7.73 (6.80)
17.73 (3.69)
  6.27 (5.84) 
15.92 (2.92) 
  5.11 (3.49) 
16.12 (3.34) 
  5.66 (5.46) 
14.77 (3.17) 
  3.46a
  5.97b 
2.02a
2.93b
2.07a
4.68c 
Itch 10.64 (2.98)   8.20 (2.54)   8.05 (2.86)   6.95 (2.41) 11.43c 3.96c 5.72c
Scratch responses
Conscious scratching 8.53 (2.80) 6.63 (2.95) 6.16 (2.87) 5.05 (2.72) 11.59c 3.64c 6.18c
Automatic scratching 5.97 (2.32) 4.66 (1.77) 4.88 (1.95) 4.26 (1.86)   7.96c 2.87b 4.69c
Scratching at night 2.32 (1.07) 1.79 (0.96) 1.68 (0.85) 1.61 (0.94)   6.86c 3.72c 3.80c
Itch-coping-patterns
Itch self-efficacy 14.41 (4.54) 19.26 (4.57) 20.64 (4.77) 20.27 (4.52) 18.56c -7.30c -6.09c
Itch catastrophizing 23.60 (9.71) 17.18 (9.44) 14.29 (9.76) 11.70 (9.36) 18.31c 6.23c 6.96c
Health-related quality of life 
Impact disease daily life 22.39 (6.20) 20.25 (6.03) 19.29 (5.88) 17.70 (5.62) 14.71c 4.40c 7.09c
Dermatology Life Quality (DLQI) 10.61 (6.82)   8.51 (5.00)   6.89 (5.44)   6.24 (5.30)   5.15b 3.45c 4.02c
Illness cognitions
Helplessness 12.18 (4.15) 11.11 (3.00) 10.66 (3.39) 10.18 (3.64) 3.45a 3.25b 3.49c
Acceptance 13.74 (3.74) 15.47 (3.48) 16.63 (4.00) 16.94 (3.74) 4.62b -3.99c -4.13c
Perceived benefits 11.08 (3.46) 12.43 (4.11) 13.52 (5.09) 13.51 (5.12) 5.97b -4.38c -3.79c
ap < 0.05; bp < 0.01; cp < 0.001.
1F-value: analyses of covariance with repeated measurements for the TC during all assessment points.
2T-value: paired t-test for the TC for differences between pre-treatment scores with scores at the 3- and 12-month follow-ups.
EASI: Eczema Area and Severity Index.
Table IV. Pre-treatment-to-follow-up changes of the treatment 
condition in the use of dermatological care 
Pre-treatment 
3-month 
follow-up 
12-month 
follow-up
Dermatological consultations
Dermatologist outpatient visits, 
mean (SD)
Dermatology day-clinic 
treatment (% of patients)
Dermatology inpatient stay  
(% of patients)
  4.73 (6.49)
30
  8
  1.87 (2.59)
  0
  3
  0.74 (0.82)
  
  0
  0
Medication and ointments 
Topical corticosteroids, mean 
(SD)
    No (% of patients)
    Mild (% of patients)
    Moderately potent  
(% of patients)
   Potent (% of patients)
   Very potent (% of patients)
Systematic medication  
(% of patients)
Itch-relieving medication 
(histamine antagonist)  
(% of patients)
  2.55 (1.11)
12
  0
18
60
10
  5
60
  2.35 (1.21)
18
  0
20
55
  7
  3
53
  2.28 (1.30)
21
  0
20
49
10
  3
33
SD: standard deviation.
Table V. Effect sizes and clinical significant changes at post-treat-
ment and both follow-up assessments in the treatment condition
Effect size Clinical significant changes
Skin 
severity Itch
25% skin 
improvement
Skin 
clearance (%)
Post-treatment 0.55 0.88 43% 47
3-month follow-up 0.46 0.89 39% 49
12-month follow-up 0.85 1.37 56% 52
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prising a cognitive-behavioural training module can 
considerably improve the outcome for patients. The 
presented follow-up results demonstrated that the post-
treatment improvements were not only sustained but had 
even increased, with the largest effects on skin severity 
and itch and scratching behaviour being observed at 
12 months. The effect sizes on the primary outcome 
parameters generally fell within the range of clinical 
significance. Accordingly, this brief, multidisciplinary 
group treatment can be considered to be successful for 
adults with AD and is at least as effective as other, more 
extensive multidisciplinary treatments (10–13). 
Our treatment programme also induced a significant 
reduction in the number of dermatological consultations 
and day-treatments, both after 3 and after 12 months, as 
well as in the number of prescriptions for itch-relieving 
medication and topical corticosteroids at 12 months. 
Only one earlier study evaluating a 10-session outpatient 
itch programme had reported a similar drop in the use of 
topical corticosteroids at the 12 month follow-up (10). 
The changes we found in the patients’ consumption 
of dermatological care are particularly relevant consi-
dering the concise multidisciplinary group treatment 
and the possible cost-effectiveness of this treatment 
approach. The attrition rate for the intervention was 
low (3%) and patients were highly committed to and 
satisfied with the programme. 
Several limitations of our study need to be taken into 
account. Obviously, using a waiting list control con-
dition means both a lack of randomization and a lack 
of control data at follow-up, as it is usually applied in 
innovative, clinical evaluation research that has prefe-
rably to be followed by a multi-centre, randomized trial 
(21). Due to this explorative character of the results of 
a non-randomized trial, the promising findings have 
to be interpreted with caution. However, comparison 
with the drop-outs and non-responders seemed to rule 
out any selection bias of the treatment sample. Al-
though the programme reduced the patients’ healthcare 
consumption after one year, these are only preliminary 
indicators of the programme’s long-term efficacy and 
future, longitudinal studies should directly look at its 
cost-effectiveness in relation to other areas of daily li-
ving. It is also important to evaluate whether the group 
treatment is effective for patients with chronic pruritus 
caused by other diseases than AD. To date, studies on 
multidisciplinary itch programmes have only inciden-
tally evaluated other populations, e.g. urticaria, nodular 
prurigo or psoriasis (11, 13). The training programme is 
currently being studied in various other patient groups, 
and the preliminary results for patients suffering from 
chronic itch due to psoriasis point to similar effects 
as those obtained in our AD sample. In addition, the 
possible mediating and moderating effects of this and 
other treatment process factors and the critical working 
mechanisms of our and other itch-coping group train-
ing programmes merit further elaboration (22). When 
focusing on cost-effectiveness issues, tailoring training 
schemes to the needs of specific patient groups or indi-
vidual patients is another key issue in clinical practice. 
Among these developments are targeted programmes 
that address specific stress-triggering mechanisms of 
chronic pruritus and e-health applications (programmes 
offered on the internet) for patients with more moderate 
itch and scratch problems (23, 24).
In conclusion, the present study demonstrates that a 
brief multidisciplinary group itch-coping programme for 
patients with AD can considerably improve the patients’ 
skin status, modify their itching and scratching patterns, 
enhance health-related quality of life and reduce the 
consumption of dermatological care in both the short 
and the longer term and implementation of the pro-
gramme can be recommended for patients with AD. 
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